Moderna (MRNA) Stock Tumbles 6% Premarket Despite Improved Q2 Revenue Amid $782M Loss

Moderna (MRNA) stock declined 6% in premarket as Q2 revenue hit $145M, net loss narrowed to $782M, and norovirus vaccine trial missed interim endpoint.

The post Moderna (MRNA) Stock Tumbles 6% Premarket Despite Improved Q2 Revenue Amid $782M Loss appeared first on Blockonomi.